EmeraMed Limited is a biotechnology firm developing the antidote – heavy metal chelator and antioxidant – Irminix® (Emeramide). The Company is working to obtain marketing authorization in the EU and the US for the treatment of mercury toxicity. Phase 1 clinical studies have been performed, and Phase 2a studies are ongoing.


Subscribe To Our Mailing List

* indicates required

Email Format